NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024
NeuroOne Medical Technologies (NMTC) has rescheduled its Virtual Investor Webinar to Friday, January 10, 2025, due to U.S. markets closure for former President Jimmy Carter's National Day of Mourning. During the webinar, CEO Dave Rosa will present the company's business model and recent achievements, including their expanded exclusive distribution agreement with Zimmer Biomet.
The company reported significant financial growth with product revenue increasing 77% to $3.5 million in fiscal year 2024. For fiscal year 2025, NeuroOne projects product revenue between $8 and $10 million, representing a substantial growth of 132% to 190%. The presentation will be followed by a Q&A session, accessible via webcast or dial-in, with playback available through January 24, 2025.
NeuroOne Medical Technologies (NMTC) ha riprogrammato il Webinar Virtuale per gli Investitori a venerdì 10 gennaio 2025, a causa della chiusura dei mercati statunitensi per il Giorno Nazionale di Lutto dell'ex Presidente Jimmy Carter. Durante il webinar, il CEO Dave Rosa presenterà il modello di business dell'azienda e i recenti risultati ottenuti, inclusa l'espansione dell'accordo di distribuzione esclusiva con Zimmer Biomet.
L'azienda ha riportato una significativa crescita finanziaria con un incremento del 77% delle entrate da prodotto, raggiungendo i 3,5 milioni di dollari nell'anno fiscale 2024. Per l'anno fiscale 2025, NeuroOne prevede entrate da prodotto tra 8 e 10 milioni di dollari, rappresentando una sostanziale crescita del 132% al 190%. La presentazione sarà seguita da una sessione di domande e risposte, accessibile tramite webcast o chiamata, con la possibilità di riascolto fino al 24 gennaio 2025.
NeuroOne Medical Technologies (NMTC) ha reprogramado su Webinar Virtual para Inversores al viernes 10 de enero de 2025, debido al cierre de los mercados de EE. UU. por el Día Nacional de Luto del ex Presidente Jimmy Carter. Durante el webinar, el CEO Dave Rosa presentará el modelo de negocio de la empresa y los logros recientes, incluyendo su acuerdo de distribución exclusiva ampliado con Zimmer Biomet.
La empresa reportó un crecimiento financiero significativo con un aumento del 77% en los ingresos de productos, alcanzando los 3.5 millones de dólares en el año fiscal 2024. Para el año fiscal 2025, NeuroOne proyecta ingresos por productos entre 8 y 10 millones de dólares, lo que representa un crecimiento sustancial del 132% al 190%. La presentación será seguida por una sesión de preguntas y respuestas, accesible a través de webcast o por llamada, con reproducción disponible hasta el 24 de enero de 2025.
NeuroOne Medical Technologies (NMTC)는 미국 시장이 전직 대통령 지미 카터의 국가 애도일로 인해 폐쇄됨에 따라 투자자 가상 웨비나를 2025년 1월 10일 금요일로 재조정했습니다. 웨비나 동안 CEO인 데이브 로사는 회사의 비즈니스 모델과 최근 성과, Zimmer Biomet와의 독점 배급 계약 확대를 포함한 내용을 발표할 것입니다.
회사는 2024 회계연도에 제품 수익이 77% 증가하여 350만 달러에 달했다고 보고했습니다. 2025 회계연도에는 NeuroOne이 800만에서 1000만 달러 사이의 제품 수익을 예상하고 있으며, 이는 132%에서 190%에 해당하는 상당한 성장입니다. 발표 후에는 웹캐스트 또는 전화로 접근할 수 있는 질문과 답변 세션이 진행되며, 2025년 1월 24일까지 재생이 가능합니다.
NeuroOne Medical Technologies (NMTC) a reprogrammé son webinaire virtuel pour investisseurs au vendredi 10 janvier 2025, en raison de la fermeture des marchés américains pour le jour national de deuil de l'ancien président Jimmy Carter. Au cours du webinaire, le CEO Dave Rosa présentera le modèle commercial de l'entreprise et les réalisations récentes, y compris leur accord de distribution exclusif élargi avec Zimmer Biomet.
L'entreprise a signalé une croissance financière significative avec une augmentation de 77% des revenus produits atteignant 3,5 millions de dollars pour l'année fiscale 2024. Pour l'année fiscale 2025, NeuroOne prévoit des revenus produits compris entre 8 et 10 millions de dollars, représentant une croissance substantielle de 132% à 190%. La présentation sera suivie d'une séance de questions-réponses, accessible par webinaire ou par téléphone, avec une rediffusion disponible jusqu'au 24 janvier 2025.
NeuroOne Medical Technologies (NMTC) hat sein virtuelles Investoren-Webinar auf Freitag, den 10. Januar 2025, verschoben, da die US-Märkte wegen des Nationalen Trauertags des ehemaligen Präsidenten Jimmy Carter geschlossen sind. Während des Webinars wird CEO Dave Rosa das Geschäftsmodell des Unternehmens und die aktuellen Erfolge vorstellen, darunter die erweiterte exklusive Vertriebsvereinbarung mit Zimmer Biomet.
Das Unternehmen berichtete von einem signifikanten finanziellen Wachstum, wobei der Produktumsatz um 77% auf 3,5 Millionen Dollar angestiegen ist im Geschäftsjahr 2024. Für das Geschäftsjahr 2025 rechnet NeuroOne mit einem Produktumsatz zwischen 8 und 10 Millionen Dollar, was einem erheblichen Wachstum von 132% bis 190% entspricht. Der Präsentation folgt eine Fragen- und Antwortsitzung, die über Webcast oder Telefon zugänglich ist, mit einer Wiedergabe, die bis zum 24. Januar 2025 verfügbar ist.
- Product revenue grew 77% to $3.5 million in FY2024
- Projected revenue growth of 132-190% for FY2025 ($8-10 million)
- Expanded exclusive distribution agreement with Zimmer Biomet
- None.
Insights
The rescheduled investor webinar announcement contains important financial data that warrants attention. The projected revenue growth from
The expanded distribution agreement with Zimmer Biomet, a major player with approximately
However, investors should note that while the growth percentages are impressive, the absolute revenue numbers are still relatively modest. The company's current market capitalization of
The expanded distribution agreement with Zimmer Biomet is particularly noteworthy in the neurotech space. NeuroOne's focus on surgical care improvements for neurological disorders positions them in a growing market segment. The revenue acceleration suggests increasing clinical adoption of their technology platform.
The partnership with Zimmer Biomet provides more than just distribution - it offers validation of NeuroOne's technology from one of the industry's leading medical device companies. This type of relationship often accelerates market penetration and can lead to future collaborative development opportunities.
Looking at the broader neurotechnology market, which is expected to grow at a CAGR of about
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025
EDEN PRAIRIE, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today a change to its Virtual Investor Webinar date due to U.S. equity markets being closed for the National Day of Mourning for former U.S. President Jimmy Carter.
Dave Rosa, Chief Executive Officer of NeuroOne, will provide an overview of the business model and discuss recent milestone achievements, including its recently expanded exclusive distribution agreement with Zimmer Biomet, one of the world’s largest medical device manufacturers. Following the Company’s recently announced product revenue growth of
The webcast, now scheduled for Friday, January 10th, will include a presentation and followed by a question-and-answer session, which can be accessed via the webcast link or dial-in numbers below.
Date: Friday, January 10, 2025
Time: 11:00 a.m. Eastern Standard Time
U.S. Dial-In (Toll Free): 877-704-4453
International Dial-In: 201-389-0920
Webcast Link: NMTC Virtual Investor Webinar
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through January 24, 2025. To listen, please call 844-512-2921 within the United States or 412-317-6671 when calling internationally, using replay passcode 13750530.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding securing a strategic partnership for distribution of the OneRF™ Ablation System, fiscal year 2025 guidance, including expectations for significant product revenue growth and margin expansion, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
FAQ
What is NeuroOne's (NMTC) projected revenue growth for fiscal year 2025?
How much did NeuroOne's (NMTC) revenue grow in fiscal year 2024?
When is NeuroOne's (NMTC) rescheduled Virtual Investor Webinar?
What major partnership did NeuroOne (NMTC) recently expand?
